FILTER
FILTERED INTERVIEW RESULTS
Joseph Colleluori
SENIOR VICE PRESIDENT CORPORATE DEVELOPMENT, LONZA GROUP
Headquartered in Switzerland and traded on the Swiss stock exchange, Lonza is a leading supplier to the pharma and biotech industries.
Ningling Wang
MANAGING PARTNER, FINNEGAN
Finnegan in Shanghai helps Chinese companies protect and enforce their IP in the US and also helps foreign clients with patent litigation in China.
Greg Scott
CEO, CHINABIO CONSULTING
ChinaBio morphed from being an angel investor in China to becoming a consultant for foreign compa-nies looking to enter the Chinese life science space.
Brian Frenzel
PRESIDENT AND CEO, TOSK, INC.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.
Conrad Bucheleres, Wei Hong & Yong Zhang
AZELIS GREATER CHINA
Azelis sources an increasing array of speciality chemicals in China and distributes across the world.
Peter Parker
MANAGING GENERAL PARTNER, BIOINNOVATION CAPITAL AND CO-FOUNDER AND DIRECTOR, LABCENTRAL
LabCental offers life science companies in Massachusetts at an early stage the facilities they need to develop
David Cory
CEO, EIGER BIOPHARMACEUTICALS
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Barbara Weber
CEO, TANGO THERAPEUTICS
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Michael Bigham & Evan Loh
PARATEK PHARMACEUTICALS
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
